Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.53 USD | +0.47% |
|
-4.23% | -28.16% |
06-28 | Needham Trims Price Target on Rocket Pharmaceuticals to $52 From $53, Maintains Buy Rating | MT |
06-28 | Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.16% | 1.95B | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target